Previous Article | Next Article 
Journal of Virology, September 2001, p. 8660-8673, Vol. 75, No. 18
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.18.8660-8673.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Activation of NF-
B by the Human Herpesvirus 8 Chemokine Receptor ORF74: Evidence for a Paracrine Model of
Kaposi's Sarcoma Pathogenesis
Shibani
Pati,1,2
Marielle
Cavrois,1
Hong-Guang
Guo,1
James S.
Foulke Jr.,1
Jynho
Kim,2
Ricardo A.
Feldman,2 and
Marvin
Reitz1,2,*
Institute of Human Virology, University of
Maryland Biotechnology Institute,1 and
Department of Microbiology and Immunology, University of
Maryland,2 Baltimore, Maryland 21201
Received 11 January 2001/Accepted 1 June 2001
 |
ABSTRACT |
Infection with human herpesvirus 8 (HHV-8), also known as Kaposi's
sarcoma (KS)-associated herpesvirus, is necessary for the development
of KS. The HHV-8 lytic-phase gene ORF74 is related to G protein-coupled
receptors, particularly interleukin-8 (IL-8) receptors. ORF74 activates
the inositol phosphate/phospholipase C pathway and the
downstream mitogen-activated protein kinases, JNK/SAPK and p38. We show
here that ORF74 also activates NF-
B independent of ligand when
expressed in KS-derived HHV-8-negative endothelial cells or primary
vascular endothelial cells. NF-
B activation was enhanced by the
chemokine GRO
, but not by IL-8. Mutation of Val to Asp in the ORF74
second cytoplasmic loop did not affect ligand-independent signaling
activity, but it greatly increased the response to GRO
. ORF74
upregulated the expression of NF-
B-dependent inflammatory cytokines
(RANTES, IL-6, IL-8, and granulocyte-macrophage colony-stimulating
factor) and adhesion molecules (VCAM-1, ICAM-1, and E-selectin).
Supernatants from transfected KS cells activated NF-
B signaling in
untransfected cells and elicited the chemotaxis of monocytoid and
T-lymphoid cells. Expression of ORF74 conferred on primary endothelial
cells a morphology that was strikingly similar to that of spindle cells present in KS lesions. Taken together, these data, demonstrating that
ORF74 activates NF-
B and induces the expression of proangiogenic and
proinflammatory factors, suggest that expression of ORF74 in a minority
of cells in KS lesions could influence uninfected cells or latently
infected cells via autocrine and paracrine mechanisms, thereby
contributing to KS pathogenesis.
 |
INTRODUCTION |
Kaposi's sarcoma (KS) is a neoplasm
of mixed cellularity that until recently was rare and occurred in three
forms: classical (in elderly males of Mediterranean descent), endemic
(in parts of Africa), and iatrogenic (in transplant patients). KS
lesions are highly vascularized and contain characteristic
spindle-shaped cells believed to be of endothelial origin, angiogenic
blood vessels, and infiltrates of immune cells. Inflammation and
angioproliferation appear to play a key role in KS development.
A fourth form (AIDS-KS) appeared with the human immunodeficiency virus
(HIV) epidemic. HIV type 1 (HIV-1) infection results in a 10,000- to
100,000-fold increase in the incidence of KS (6, 7, 55)
but is not a primary cause of KS, since the other three forms of KS are
negative for HIV-1. Thus, HIV-1, although not necessary for KS, is a
very powerful cofactor. A new herpesvirus called KS-associated
herpesvirus (KSHV) or, more formally, human herpesvirus 8 (HHV-8) was
discovered in KS lesions (16) and was found to be present
in virtually all cases of the four forms of KS, as well as in primary
effusion lymphomas (14). An increase in HHV-8 antibody
levels in serum and viremia precedes the onset of KS by 1 or 2 years
(27, 41, 47, 57, 68). Taken together, these data indicate
that HHV-8 infection is necessary for KS.
In spite of the strong epidemiological association of HHV-8 with KS,
its pathogenic role(s) is not clear. The apparent prevalence of HHV-8
in normal populations ranges from a small percentage of the general
population in the United States, the Caribbean, and countries in
Southeast Asia (1, 61) to >50% in parts of Africa
(3, 28, 44). This far exceeds the rate of KS in these
regions, suggesting that although HHV-8 is necessary for KS, it is
highly inefficient. Many genes of HHV-8 have been shown to transform
cells, but infection with HHV-8 does not generally transform cells.
Infection of endothelial cells in vitro greatly extends their life
span, although only about 5% of the cells are infected at any given
time (23). In early KS lesions, a minority of the spindle
cells believed to constitute the abnormal cell population is infected
(8). In later lesions, although most spindle cells are
infected, the majority of infected cells are in viral latency, and
lytic replication is occurring in only a few cells (8,
64). Taken together, these data suggest that HHV-8 infection
could influence uninfected cells and contribute to KS pathogenesis by
paracrine mechanisms involving soluble factors secreted by infected
lytic-phase cells.
Lytic viral gene products or cellular gene products induced by them
could act as soluble paracrine factors. HHV-8 codes for at least four
biologically active secreted lytic-phase proteins: a viral
interleukin-6 (vIL-6) that has functional similarities to its cellular
homologue (46, 50, 51), and three homologues of cellular
chemokines (9, 38, 46, 51) that can elicit angiogenesis and chemotaxis. HHV-8 also has genes, including K1 (40), several v-IRFs (12, 26), v-FLIP
(65), K15 (32, 54), and ORF74 (4,
33), that are related to cellular signal transduction genes and
factors and that could induce the expression of soluble paracrine factors.
ORF74, a chemokine (IL-8) receptor homologue, is an early lytic-phase
gene (37, 60) that is expressed in KS lesions at a very
low level (33). ORF74 is an attractive candidate for a
gene whose expression could alter the behavior of adjacent uninfected or latently infected cells. Indeed, it induces angiogenesis and vascular endothelial growth factor (VEGF) expression in vitro and in xenotransplants in mice (5). Transgenic mice
expressing ORF74, regulated by a T-cell-specific promoter, develop
angioproliferative lesions that exhibit many of the characteristics of
KS but do not develop lymphoproliferative diseases, suggesting that
paracrine mechanisms may cause their KS-like lesions (15,
69). ORF74 has been shown to signal constitutively through the
inositol phosphate/phospholipase C pathways and to activate downstream
mitogen-activated protein (MAP) kinases p38 and JNK/SAP (4,
62). Many cellular chemokines bind to ORF74, including IL-8 and
Gro
. Some enhance or inhibit, but most fail to change, its ability
to signal through these pathways (29, 30, 31).
Inflammation is thought to play a major role in the developmental
course of KS. Inflammatory cytokines, adhesion molecules, and
endothelial cell activation are all centrally involved in this process
(20), and the expression of many of these factors depends
upon activation of the transcriptional regulatory factor NF-
B. We
therefore sought to determine whether expression of ORF74 affected
NF-
B activity and resulted in the secretion of inflammatory factors
other than VEGF that could promote the development of KS by paracrine
mechanisms. We present the results of these studies, which indicate
that ORF74 indeed enhances NF-
B activation, resulting in the
induction of expression of several NF-
B-dependent proinflammatory
and pro-angiogenic cytokines, chemokines, and cell adhesion molecules.
 |
MATERIALS AND METHODS |
Cell culture and retroviral infections.
Human umbilical vein
endothelial cells (HUVECs) and dermal microvascular endothelial cells
(dMVECs) were obtained from Cell Systems Corp. (CS-C) (Kirkland,
Wash.). Cells were maintained in CS-C complete medium in a 5%
CO2 humidified incubator. HUVECs were expanded
and used for experiments between passages 4 and 5. A. Albini (Istituto
Nazionale per la Ricerca sul Cancro, Genoa, Italy) kindly provided
KSIMM cells (2). KSIMM cells were maintained in RPMI (Life
Technologies, Inc. [LTI], Gaithersburg, Md.) with 10%
heat-inactivated fetal bovine serum (FBS; LTI) in a 5%
CO2 humidified incubator. Penicillin G (100 U/ml)
and 100 µg of streptomycin/ml were added to all culture media. For
retroviral infections, HUVECs or dMVECs (passages 4 and 5) were treated
with Polybrene (6 µg/ml) 12 h prior to infection. Supernatants
containing retrovirus were prepared from the Moloney murine leukemia
virus-based retroviral packaging cell line Phoenix(Ampho) by
transfection with pMIGR1(ORF74) or pMIGR1 empty vector. W. Pear
(University of Pennsylvania, Philadelphia) kindly provided the MIGR1
vector (53). Retrovirus preparations were added to the
HUVECs or dMVECs, which were then gently rocked for 1 h. The virus
titer was determined by expression of green fluorescent protein (GFP),
translated from an independent ribosome entry site (IRES) in the
retroviral vector from the same cistron containing the inserted gene.
Cells were refed 24 h postinfection with fresh media.
Plasmids and transfections.
Cells were transfected with
various plasmid constructs using Fugene 6 (Boehringer Mannheim,
Indianapolis, Ind.) according to the manufacturer's instructions.
Transfection efficiencies were estimated by cotransfection of a
-galactosidase (
-Gal) expression vector pCMV-
-Gal
(Stratagene) or GFP (Green Lantern; Stratagene). Lysates were assayed
for
-Gal activity, and cells were counted for reporter gene
expression. The dominant-negative (DN) mutant I
B
32A/36A was a
kind gift from J. DiDonato (University of California, San Diego, School
of Medicine, La Jolla) (18). The DN constructs for
IKK75
(K44A) and IKK
(K44A) were generously provided by D. Goeddel (Tularik, South San Francisco, Calif.). The DN mutant of AKT
(AKT-K179 M) was obtained from the lab of M. Greenberg (Harvard Medical
School, Boston, Mass.) (19). The mutant construct of ORF74
(V142D) was generated as described below. LY294002, wortmannin, and the
p38 inhibitor SB203580 were obtained from Sigma, St. Louis, Mo. They
were added to cell culture media for 4 to 6 h on day 1 posttransfection at final concentrations of 40 µM, 20 nM, and 10 µM, respectively. Gro
and IL-8 (R&D Systems, Minneapolis, Minn.)
were added to the cell culture media at different concentrations (20 to
100 nM) 1 h prior to cell harvest for gel shift assays and 4 h prior to harvest for luciferase assays.
Luciferase reporter gene assays.
The NF-
B reporter
construct expresses the firefly luciferase gene under regulation by a
synthetic promoter containing five tandem binding sites for NF-
B
(Stratagene, La Jolla, Calif.). AP1, CRE, and p53 luciferase reporter
gene constructs were also obtained from Stratagene. KSIMM cells were
transfected using Fugene 6 with 0.5 µg of the NF-
B luciferase
reporter-gene construct, ORF74-pSG5, or pSG5 alone, various DN
constructs, and pCMV-
-Gal (Stratagene). The amount of total DNA
transfected was equalized with the appropriate amounts of control
vectors. At 20 h posttransfection, cells were harvested and lysed
in cell lysis buffer (a proprietary formulation) (Promega, Madison,
Wis.). Protein concentration was normalized by bicinchoninic acid (BCA)
assay (Pierce Biochemicals, Rockford, Ill.). Luciferase activity was
determined using Luciferase Assay Reagent (Promega) and a luminometer
(Turner Designs, Sunnyvale, Calif.). Transfection efficiencies were
normalized by assaying
-Gal activity from the cotransfected
pCMV-
-Gal.
Western blot analysis.
KSIMM cells were transfected with
pSG5 control vector or ORF74-pSG5 using Fugene 6 (Boehringer Mannheim).
Cells were harvested and lysed in lysis buffer (5% Triton X-100 in
phosphate-buffered saline [PBS], pH 7.4) with protease inhibitors
(complete minileupeptin, aprotinin, and Pefabloc) (Boehringer
Mannheim). Protein quantification was carried out by BCA assay. Protein
was loaded in each well and subjected to sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) on 4 to 12%
gels. Transfer to nitrocellulose membranes was performed in transfer
buffer (12 mM Tris base; 96 mM glycine, pH 8.3; 15% methanol).
Membranes were probed with primary antibodies to phospho-Akt (ser473),
Akt (New England Biolabs, Beverly, Mass.),
-actin (Sigma), or ORF74
(rabbit polyclonal
gift of Gary Hayward, Johns Hopkins University).
Secondary antibody conjugated to horseradish peroxidase (HRP) was used.
Protein was detected using an enhanced chemiluminescence detection
system (Amersham Pharmacia Biotech, Piscataway, N.J.) according to the
manufacturer's protocol.
Cytokine quantitation by ELISA.
KSIMM cells were transfected
with pSG5-ORF74 or pSG5 alone using Fugene 6. Cell counts were taken to
ensure equality of cell numbers in different wells. Supernatants from
equal numbers of cells were collected 20 h posttransfection and
centrifuged (12,000 rpm, 15 min) to remove cell debris. Supernatants
were also collected from HUVECs 3 days after infection with the
MIGR1-ORF74 or the control MIGR1 retrovirus. Cytokines in supernatants
were quantified using commercial enzyme-linked immunosorbent assay
(ELISA) plates precoated with the appropriate antibodies (R&D Systems).
Samples were added to plates, which were incubated at room temperature for 1 h. Plates were washed four times with PBS-0.5% Tween 20, and biotinylated anticytokine antibodies were added to the plates, which were incubated at room temperature for 1 h. After a washing step, streptavidin-HRP was added to the plates for 30 min, and the
plates were washed again and then incubated with TMB
(3,3',5,5'-tetramethylbenzidine) substrate for 20 min. Reactions were
stopped with 2 N H2SO4, and the absorbance at 450 to 570 nm was determined. All readings were done
in duplicate.
Flow cytometric analysis.
KSIMM cells were transfected with
pSG5-ORF74 or pSG5 alone. Cells were detached 20 h
posttransfection with 1 mM EDTA and counted. Aliquots (0.5 × 106) of transfected cells were washed twice in
ice-cold PBS with 2% FBS. Cells treated with tumor necrosis factor
alpha (TNF-
; 5 ng/ml) were included as a positive control for
induction of adhesion marker expression. Appropriate antibodies were
aliquoted into each tube and incubated on ice in the dark for 60 min.
Cells were washed twice in PBS-2% FBS and fixed in 0.5 ml of 2%
paraformaldehyde. Samples were analyzed using a Becton-Dickinson
FACSCalibur flow cytometer. Phycoerythrin (PE)-conjugated antibodies
for VCAM-1, ICAM-1, and E-selectin were obtained from PharMingen (San
Diego, Calif.). Appropriate isotype controls were used for each
antibody as a control for nonspecific antibody binding.
Generation of ORF74 expression constructs.
By using DNA from
a lambda clone of HHV-8 (
6-1) (33) containing ORFs 72 to 75 (GenBank accession number U82242) as a template, a fragment
containing ORF74 was generated by PCR amplification using Bio-X-Act
polymerase (Bioline, Reno, Nev.) and primers ORF74sense (5'-CGCAT
GAATTCCTTGTTATTGTAGCATGGCGG-3') and ORF74antisense
(5'-CGATG AGATCTGGGCTACGTGGTGGCG-3'). The
fragment was separated on an agarose gel, extracted with a Concert
Rapid Gel Extraction kit (LTI), and digested with EcoRI and
BglII (underlined). The purified fragment was ligated into
the EcoRI/BglII sites of the expression plasmid vector pSG5 (Stratagene) with T4 ligase and transfected into STBL2 bacterial cells (LTI). Transformants were screened for the presence of
the ORF74 insert by restriction digest analysis of DNA minipreps using
BglII and EcoRI. Two clones were identified and
sequenced at the University of Maryland, Baltimore, Biopolymer Core
Facility with an ABI Prism model 373, version 3.0, DNA sequencer to
verify the presence of the correct open reading frame.
A retroviral construct expressing ORF74 was prepared using pMIGR1
(53), which expresses GFP using an encephalomyocarditis virus (EMCV)-derived IRES and the same promoter used to drive ORF74
expression. To clone ORF74 into pMIGR1,
6-1 DNA was used as a
template for PCR amplification with Bio-X-Act polymerase and the
primers 495B
(5'-CTCTAGATCTTTGTTATTGTTGGCCATGGC-3') and 494 (5'-CAACGAATTCCTACGTGGTGGCGCCGGAC-3'). The PCR
product was purified from an agarose gel with the Concert Rapid PCR
Purification Kit (LTI), digested with BglII and
EcoRI, repurified as described above, ligated into the
BglII/EcoRI sites of pMIGR1 using T4 DNA ligase,
and transfected into STBL2 cells. Transformants were screened for the
presence of the ORF74 insert by restriction digest analysis of DNA
minipreps using BglII and EcoRI. Endotoxin-free
plasmid DNA was prepared from two positive clones using the EndoFree
Plasmid Maxi Kit (Qiagen, Valencia, Calif.). Both clones were analyzed by DNA sequencing and found to contain the correct ORF.
Generation of mutant ORF74 (V142D).
The V142D mutant of
ORF74 was generated by PCR in two steps. (i) ORF74 was PCR amplified
from pMIGR1(ORF74) in two segments that overlapped in the region of
Val142. Val was changed to Asp in both fragments using a partly
mismatched primer. The primers for the 5' portion of ORF74 were 495B
and MP3
(5'-TGCCACCAGGAGGTACCTATCTTGACTGACGCACAC-3') and
for the 3' portion were 494 and MP1
(5'-GTGCGTCAGTCTAGATAGGTACCTCCTGGTGGCATA-3'). The
mismatched bases are in boldface italics. The PCR products were gel
purified as described above. (ii) The two fragments were joined by PCR
overlap extension. An equimolar mixture of the two purified mutant
fragments was amplified by PCR using the outer primers 495B and 494. The resultant PCR product was gel purified as before, digested with
BglII and EcoRI, repurified, ligated into the
cognate sites of MIGR1, and transfected into STBL2 cells. Transformants
were grown and analyzed by digestion with XbaI, which is
unique to the mutant ORF74 sequence, and EcoRI plus
BglII. Endotoxin-free plasmid DNA was prepared using
EndoFree Maxi Plasmid Kit (Qiagen) from two positive clones. The mutant
ORF74 sequence was confirmed by sequence analysis of both clones.
Chemotaxis assays.
Chemotaxis assays were performed with the
U937 monocytoid and Jurkat CD4+ T-lymphoid cell
lines (American Type Culture Collection, Manassas, Va.) as described
previously (11). Cells were harvested and resuspended at a
concentration of 1.6 × 106 cells/ml in
assay medium (RPMI 1640 containing 25 mM HEPES without phenol red or
sodium bicarbonate). Cells then were labeled with 0.1 µM Calcein AM
(Molecular Probes, Eugene, Oreg.) and an equal volume of Pluronic F-127
(Molecular Probes) at 37°C for 30 min. After being loaded, the cells
were washed twice in assay medium and resuspended at a concentration of
4 × 106 cells/ml. Chemotaxis was measured
in 96-well ChemoTx disposable chambers with 5-µm-diameter pores
(Neuroprobe, Cabin John, Md.). Supernatants from ORF74- or control
vector-transfected cells (total volume, 29 µl) were placed in the
lower chamber and covered with a filter. A 25-µl drop containing
105 cells was then placed on the filter top. The
chamber was placed in a 37°C incubator for 6 h. The fluorescence
emission in the lower chamber was measured at 517 nm by using a Victor
fluorescence plate reader (Wallac, Gaithersburg, Md.). The fluorescence
values were converted to cell number based on a standard curve
generated by staining serial concentrations of cells with 0.1 µM
Calcein AM as described above.
Gel shift assays.
Cells were transfected with pSG5-ORF74 or
pSG5 alone. Day 1 posttransfection cells were harvested, and nuclear
extracts were prepared. Cells were centrifuged at 4°C and 1,200 rpm
for 10 min, washed in ice-cold PBS, suspended in 100 µl of sucrose
buffer (0.32 M sucrose; 3 mM CaCl2; 2 mM
magnesium acetate; 0.1 mM EDTA, pH 8; 10 mM Tris-HCl, pH 7.9; 1 mM dithiothreitol [DTT], 1 mM phenylmethylsulfonyl fluoride [PMSF];
0.5% NP-40; 1 mM NaF; 1 mM
Na3VO4; 0.01 mg of
aprotinin/ml; 0.01 mg of leupeptin/ml; 0.01 mg of pepstatin A/ml) per
107 cells and incubated on ice. After
centrifugation at 600 × g for 5 min at 4°C, the
supernatants were removed and the nuclear pellets were washed in
sucrose buffer lacking NP-40. Nuclear pellets were lysed in 50 µl of
Dignam buffer (20 mM Tris-Cl, pH 7.9; 1.5 mM MgCl2; 420 mM NaCl; 2 mM EDTA, pH 8; 1 mM PMSF; 1 mM NaF; 1 mM Na3VO4; 0.01 mg of aprotinin/ml; 0.01 mg of leupeptin/ml; 0.01 mg of pepstatin A/ml;
50 mM
-glycerol phosphate). Lysed pellets were incubated on ice for
20 min and centrifuged at 9,000 × g. Supernatants were
collected and stored at -80°C. Oligonucleotide probes containing
NF-
B binding sites were labeled with
[
-32P]dCTP. Protein concentrations of each
sample were determined by BCA assay. A total of 4 to 5 µg of nuclear
protein was incubated on ice in DNA binding buffer (10 mM HEPES, pH
7.9; 50 mM KCl; 0.2 mM EDTA; 2.5 mM DTT; 10% glycerol; 0.05% NP-40),
2 to 3 µg of poly(dI-dC), and labeled NF-
B probe (4 × 104 cpm). Samples were electrophoresed on a 4%
nondenaturing acrylamide gel, and the gel was dried and autoradiographed.
ELISA-based NF-
B DNA binding assay.
KSIMM cells were
transfected with 100 or 500 ng of pSG5-ORF74 or pSG5 in
25-cm2 plates. Cells were harvested at 16 h
posttransfection. Alternatively, cell lysates were prepared from dMVECs
infected with retrovirus MIGR1-ORF74 or MIGR1. Whole-cell lysates were
assayed for activated NF-
B DNA binding ability by an ELISA-based
assay kit (Active Motif, Carlsbad, Calif.). This assay, which has been
reported to be more sensitive than standard gel shift assays
(56), uses 96-well plates coated with oligonucleotides
containing the NF-
B consensus site (5'-GGGACTTTCC-3').
Cells were lysed in 100 µl of lysis buffer (20 mM HEPES, 0.35 M NaCl,
20% glycerol, 1% NP-40, 1 mM MgCl2 · 6H2O, 0.5 mM EDTA, 0.1 mM EGTA) containing a
protease inhibitor cocktail provided in the kit. Various amounts of
lysate were incubated in binding buffer [4 mM HEPES, 100 mM KCl, 8%
glycerol, 5 mM DTT, 0.2% bovine serum albumin, 0.016% poly(dI-dC)]
for 1 h. Excess (20 pmol) mutant probe
(5'-AGTTGAGGCCATTTCCCAGGC-3') and wild-type probe
(5'-AGTTGAGGGGACTTTCCCAGGC-3') were added to reactions in
the competition experiments. Plates were washed three times in wash
buffer (PBS, 0.1% Tween 20), incubated with rabbit anti-p65 antibody
for an hour, rewashed three times, incubated with an
HRP-conjugated anti-rabbit immunoglobulin G (IgG) antibody for
1 h, and rewashed four times. Wells were incubated with 100 µl
of TMB for 5 min, and 100 µl of stop solution was added as per the
kit directions. Plates were analyzed with an ELISA plate reader at 450 nm with a reference wavelength of 655 nm.
 |
RESULTS |
ORF74 activates NF-
B.
Transient expression of ORF74 in
KSIMM cells, an HHV-8-negative KS-derived cell line, resulted in the
activation of an NF-
B-sensitive reporter gene. As shown in Fig.
1A, NF-
B activation was seen upon
transfection using as little as 20 ng of ORF74-pSG5 per well. There was
a progressive increase in NF-
B activity with increasing amounts of
transfected ORF74 DNA. In samples transfected with 500 ng of ORF74
plasmid DNA, NF-
B was activated about eightfold above the baseline.
Transfection with an empty control vector failed to appreciably induce
NF-
B. Figure 1B shows that the levels of ORF74 protein, as judged by
Western blotting, roughly correlated both with the increasing amounts
of transfected ORF74 plasmid DNA and with the corresponding increase in
NF-
B activity seen in Fig. 1A. The fuzzy bands representing ORF74 in
the Western blots have an apparent molecular mass of about 45 kDa,
somewhat larger than the calculated mass of 38 kDa. This is likely due to glycosylation of the multiple consensus glycosylation sites in ORF74
or to other posttranslational modifications.

View larger version (44K):
[in this window]
[in a new window]
|
FIG. 1.
Dose response of ORF74-induced activation of NF- B in
KSIMM cells. (A) Dose response to transfected ORF74. KSIMM cells
(105) were transfected with a NF- B luciferase reporter
construct (100 ng/sample) and increasing amounts (20 to 500 ng) of an
expression vector encoding ORF74 (ORF74-pSG5). Total input DNA was
balanced with the empty expression vector (pSG5). A CMV- -Gal vector
(200 ng) was cotransfected to serve as an internal control for the
efficiency of transfection. Transfection efficiencies were ca. 20%.
Cells were harvested and assayed for luciferase and -Gal activity
24 h after transfection. Luciferase values are expressed as
relative light units (RLU) and were normalized to the constant
-Gal activity. The values shown are averages of three independent
samples, with standard deviations represented by the error bars. (B)
ORF74 protein expression. KSIMM cells were transfected with increasing
amounts of ORF74-pSG5 DNA (lanes 2 to 5) as described for panel A. Cell
lysates were analyzed for ORF74 protein by SDS-PAGE and Western
blotting. Lane 1 contains protein lysate from KSIMM cells transfected
with pSG5 alone. The band in lane 1 is a nonspecific band given by the
ORF74 rabbit polyclonal antibody. Blots were stripped and reprobed with
an antibody to -actin to ensure that equal amounts of protein were
loaded in each lane.
|
|
Figure
2a shows the kinetics of NF-

B
activation by ORF74. For samples transiently transfected with 100 ng of
ORF74 plasmid
DNA, activation was rapid, reaching a maximum within
24 h of transfection
and then diminishing completely by 72 h.
For samples transfected
with 500 ng of DNA NF-

B activity reached a
maximum by 24 h and
diminished slightly thereafter but was still
evident at 72 h posttransfection.
We wanted to determine how
NF-

B activation kinetics at the two
input levels of plasmid DNA (100 ng and 500 ng) correlated with
ORF74 protein levels. As shown in Fig.
2B, the NF-

B activity
over time correlates well with ORF74 protein
levels. In samples
transfected with 100 ng of ORF 74, protein
expression is maximal
at 24 h and diminishes to undetectable
levels by 72 h posttransfection.
In samples transfected with 500 ng of ORF74 DNA, protein expression
is also maximal at 24 h and
diminishes slightly thereafter, but
it is still present at 72 h
posttransfection.

View larger version (41K):
[in this window]
[in a new window]
|
FIG. 2.
Time course of ORF74-induced activation of NF- B in
KSIMM cells. (A) Time course of NF- B signaling. KSIMM cells
(105) were transfected with an NF- B luciferase reporter
construct (100 ng) and 100 or 500 ng of pSG5-ORF74. Transfection
efficiencies were ca. 20%. Controls were transfected with pSG5 alone.
Cells were harvested at the indicated time points and assayed for
luciferase activity. Readings are expressed as the fold increase of
luciferase above the control vector-transfected cells. Values shown are
averages of three independent samples, with standard deviations
represented by the error bars. (B) ORF74 protein expression. KSIMM
cells were transfected with 100 ng (lanes 1 to 4) or 500 ng (lanes 6 to
9) of ORF74 DNA as described for panel A. The cells for lanes 5 and 10 (designated "c" for control) were transfected with pSG5 alone and
harvested at 24 h posttransfection. Cell lysates were analyzed for
ORF74 protein by SDS-PAGE and Western blotting. Blots were stripped and
reprobed with an antibody to -actin to ensure that equal amounts of
protein were loaded into each lane.
|
|
Electrophoretic mobility gel shift assays (EMSAs) were performed to
determine whether ORF74 activation of NF-

B correlated
with induction
of protein binding to NF-

B sites. Figure
3A shows
that this is indeed the case.
Retardation of migration of an oligonucleotide
containing a consensus
NF-

B site was evident after incubation
with nuclear extracts
prepared from ORF74-transfected cells. Supershift
assays were performed
using antibodies to members of the NF-

B
family. As shown in Fig.
3A,
the bound complexes were shifted
by antibodies to p65(RelA) and p50,
suggesting that NF-

B binding
was at least in part by p65-p50
heterodimers. To further characterize
NF-

B binding, an ELISA-based
DNA-binding assay was performed
for p65 (see Materials and Methods)
(
56). In this assay, the
NF-

B complex bound to an
immobilized oligonucleotide containing
an NF-

B consensus DNA binding
site is detected with an antibody
to p65. A secondary antibody
conjugated to HRP provides a colorimetric
readout. Figure
3B shows that
cell lysates from KSIMM transfected
with either 100 or 500 ng of
pSG5-ORF74 show enhanced NF-

B binding
to the oligonucleotide
containing the consensus site. This increase
binding is inhibited by
addition of excess soluble wild-type oligonucleotide
but not excess
oligonucleotide containing a mutant consensus site.

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 3.
Induction of NF- B binding activity by ORF74. (A)
NF- B binding activity is induced by ORF74. KSIMM cells were
transfected with ORF74-pSG5 or pSG5 control vector; the transfection
efficiency was 28%. Cells were harvested and nuclear extracts were
prepared and used in an electrophoretic mobility shift assay as
described in Materials and Methods. Supershift assays were performed
with the indicated antibodies. Complexes supershifted with p65 antibody
are marked with an asterisk. (B) ELISA-based NF- B DNA binding assay.
KSIMM cells were transfected with 100 or 500 ng of ORF74-pSG5 or pSG5.
Cells were harvested at 16 h posttransfection. Cell lysates were
assayed for NF- B DNA binding using an ELISA-based assay kit (Active
Motif) in which 96-well plates are coated with oligonucleotides
containing the NF- B consensus site. Excess (20 pmol) mutant
(ORF/exc. mut oligo) or wild-type (ORF/exc. wt oligo) probes were added
to the indicated samples as competitors. Plates were incubated with
rabbit anti-p65 antibody for 1 h, followed by an
HRP-conjugated anti-rabbit IgG, and developed with TMB (see
Materials and Methods). The binding was quantified
spectrophotometrically.
|
|
Mutant ORF74(V142D) constitutively activates NF-
B.
One of
the striking characteristics of ORF74-mediated signaling is its
activity in the absence of ligand. Recent work by Burger et al.
(10) has shown that mutation of a DRY motif present in the
second transmembrane loop of the IL-8 receptor CXCR2, which is common
to most cellular chemokine receptors, results in ligand-independent signaling by CXCR2. We were interested in whether the opposite change
in ORF74, from VRY to DRY, would eliminate the ligand-independent activation of NF-
B. Figure 4 shows
that the mutant ORF74(V142D) retained the ability to activate NF-
B
in the absence of added ligand and did so at a slightly enhanced level
compared to the wild-type ORF74. Interestingly, however, signaling
by ORF74(V142D) was greatly enhanced in the presence of Gro
, an
ORF74 ligand. Gro
at 20 nM did not enhance activation of NF-
B by
wild-type ORF74 compared with >8-fold activation of ORF74(V142/D)
above that for the control. Wild-type ORF74 could only be stimulated at
the increased dose of 100 nM Gro
, with the mutant showing a much
more pronounced NF
B activation at 100 nM Gro
. Cells
transfected with an empty control vector were not affected by addition
of Gro
at either concentration. IL-8 did not enhance the activation of NF-
B by either mutant or wild-type ORF74 constructs (data not
shown).

View larger version (17K):
[in this window]
[in a new window]
|
FIG. 4.
Inducible NF- B signaling by mutant ORF74. KSIMM cells
(105) were transfected with an NF- B luciferase reporter
plasmid and wild-type ORF74 (ORF74-MIGR1), mutant ORF74 (V142D) in the
same vector, or the control vector (MIGR1). At 16 h
posttransfection, cells were treated with Gro for 4 h. Cells
were harvested, lysed, and assayed for luciferase activity as described
in Materials and Methods. Readings are expressed as the fold increase
of luciferase above that of the control vector-transfected cells.
Transfection efficiencies were ca. 25%.
|
|
ORF74 activates NF-
B in primary endothelial cells.
To
determine whether ORF74 could activate NF-
B in primary endothelial
cells, dMVECs were infected with a retrovirus expressing ORF74 from a
Moloney murine leukemia virus long terminal repeat (LTR) (see Materials
and Methods). This retrovirus (MIGR1) also expresses GFP using an
EMCV-derived IRES and the same promoter used to drive ORF74, thereby
allowing visualization of infected cells expressing ORF74. Lysates from
these cells were assayed for activation of NF-
B DNA binding by the
ELISA-based NF-
B DNA binding assay described above. Figure
5A shows that cell lysates from dMVECs
infected with a retrovirus expressing ORF74 show enhanced NF-
B DNA
binding relative to lysates from control retrovirus-infected cells.
This increase in NF-
B DNA binding is inhibited by addition of excess
wild-type oligonucleotide but not excess oligonucleotide containing a
mutant consensus site. Western blots (Fig. 5B) show that ORF74 protein
is expressed but at somewhat lower levels than in KSIMM cells
transfected with 100 ng of ORF74 DNA and analyzed 24 h
posttransfection.

View larger version (17K):
[in this window]
[in a new window]
|
FIG. 5.
ORF74 activates NF- B in primary endothelial cells.
(A) Activation of NF- B DNA binding in endothelial cells expressing
ORF74. dMVECs were infected with a retrovirus expressing ORF74 from the
Moloney murine leukemia virus LTR (ORF74-MIGR1) (see Materials and
Methods) or control virus alone (MIGR1). Lysates from these cells were
assayed for activation of NF- B DNA binding by ELISA-based NF- B
DNA-binding assays (see Materials and Methods). Excess (20 pmol) mutant
probe (ORF/exc. mut oligo) or probes (ORF/exc. wt oligo) wild-type were
added to reactions as competitors. (B) Expression of ORF74 protein in
primary endothelial cells. Cell lysates were harvested 10 days
postinfection, and 25 µg of protein lysate was analyzed by SDS-PAGE
and Western blotting for ORF74. Twenty-five micrograms of protein
lysate from KSIMM cells transfected with 100 ng of ORF74-pSG5 or empty
vector (pSG5) was included for comparison of the protein expression
levels. Lysates from transfected cells were harvested at 24 h
posttransfection. The transfection efficiency was 25%. Blots were
stripped and reprobed with an antibody to -actin to ensure that
equal amounts of protein were loaded in each lane.
|
|
Expression of ORF74 in endothelial cells results in spindle-shaped
cells.
Interestingly, transduction of ORF74 into primary
endothelial cells (both HUVECs and dMVECs) using a retroviral vector
resulted in profound changes in their morphology. As shown in Fig.
6B and D, cells infected
with the ORF74 retrovirus assume a spindle shape compared to control virus-infected cells (Fig. 6A and C), an appearance strikingly similar to that of the spindle cells present in KS lesions. Infection efficiencies for both control and ORF74-expressing viruses were ca. 80%, as determined by counting GFP-positive cells.


View larger version (203K):
[in this window]
[in a new window]
|
FIG. 6.
Induction of spindle morphology in primary endothelial
cells by ORF74. dMVECs (passages 4 and 5) were infected with the
retroviral expression construct MIGR1-ORF74 (B and D) or the control
vector MIGR (A and C). A reporter gene for GFP is expressed on the same
mRNA as ORF74 and translated from an IRES in the retroviral vector (see
Materials and Methods). Fluorescence was detected using a 395-nm
excitation light source for illumination as seen in panels C and D. Photographs were taken by phase-contrast microscopy at 20×
magnification at 10 days postinfection. The whitish hue on cells in
panels C and D represents GFP expression. Panels A and B (4×
magnification) show the morphologic changes in the culture population
as a whole (infection efficiency was ca. 80%).
|
|
DN mutants of IKK
, IKK
, and I
B
inhibit activation of
NF-
B by ORF74.
To further characterize NF-
B activation by
ORF74, we tested whether DN mutants of proteins involved in NF-
B
signaling could inhibit the observed activation. In unstimulated cells,
NF-
B is sequestered in an inactive form in the cytoplasm bound to
I
proteins. Appropriate stimulation of cells, by viral genes or exogenous stimuli such as TNF-
, leads to a rapid phosphorylation by
the I
B kinase (IKK) complex. IKK then phosphorylates I
B, which is
ubiquitinated and degraded, freeing NF-
B to translocate to the
nucleus and activate transcription of its target genes. Figure
7 shows that DN IKK
and DN I
B
completely inhibited NF-
B activation by ORF74 in KSIMM cells.
Partial inhibition was obtained under the same conditions with
DNIKK
, another kinase in the NF-
B pathway.

View larger version (15K):
[in this window]
[in a new window]
|
FIG. 7.
Inhibition of NF- B activation by ORF74 by DN mutants.
KSIMM cells (3 × 105 cells) were transfected with
pSG5-ORF74, the NF- B luciferase reporter plasmid, and increasing
amounts of the indicated DN mutant expression constructs. Total DNA
inputs were equalized with control vector. Cells were lysed and
luciferase expression was quantified at 18 h posttransfection.
KSIMM cells were transfected with ORF74 and increasing amounts of DN
constructs of IKK , IKK , and I B. All samples were analyzed in
triplicate, and the values were averaged. The transfection efficiencies
were ca. 30%.
|
|
ORF74 is known to activate the AP1 and CRE transcription factor
pathways, which are downstream of the MAP kinase pathways.
To
understand how the levels of activation of NF-

B by ORF74 compare
with those of AP1 and CRE, KSIMM cells were transfected with luciferase
reporter gene constructs and ORF74 (200 ng) or pSG5 (200 ng).
p53
luciferase was included as a negative control to ensure that
ORF74-mediated activation of these reporter constructs was specific.
The fold activations of NF-

B, AP1, CRE, and p53 luciferase by
ORF74
were 5.5, 5.6, 4.7, and 1, respectively (data not shown).
These results
indicate that the activation of NF-

B by ORF74 in
reporter gene
assays is similar to that of other factors known
to be activated by
ORF74 and has
specificity.
PI 3-kinase inhibitors and DN Akt, but not a p38 inhibitor, block
activation of NF-
B by ORF74.
To further elucidate the mechanism
of NF-
B activation by ORF74, KSIMM cells transfected with pSG5-ORF74
were treated with either LY294002 and wortmannin, two specific
inhibitors of phosphatidylinositol 3-kinase (PI 3-kinase), or SB203580,
a specific inhibitor of p38 MAP kinase. Alternatively, samples were
cotransfected with an expression construct of a DN mutant of Akt(K179M)
(19). PI 3-kinase and its downstream kinase Akt activate
NF-
B in response to stimuli such as TNF-
and platelet-derived
growth factor (PDGF) (52, 58). The appropriate
concentrations of LY294002 and DN Akt were determined by their ability
to fully abrogate NF-
B activation in KSIMM cells induced by TNF-
(data not shown). NF-
B activation by ORF74 was almost completely
inhibited by 40 µM LY294002 and 20 nM wortmannin (Fig.
8A). Consistent with the possibility that activation by ORF74 involves signaling through PI 3-kinase and Akt,
cotransfection with 0.2 µg of DN Akt inhibited NF-
B activation, although inhibition was incomplete. The p38 inhibitor SB203580 (10 µM) neither inhibited nor enhanced NF-
B activation by ORF74. Furthermore, Western blots of Akt (Fig. 8B) showed enhanced
phosphorylation of Akt in cells expressing ORF74. Quantification of the
bands using a Storm PhosphorImager (Molecular Dynamics, Sunnyvale,
Calif.) showed that the ratio of the intensity of phosphorylated Akt to the intensity of total Akt was 0.4 when pSG5 was transfected, compared
to 0.83 when ORF74-pSG5 was cotransfected and 0.23 with the LY294002
control.

View larger version (17K):
[in this window]
[in a new window]
|
FIG. 8.
Involvement of PI 3-kinase and Akt but not p38 in
NF- B activation by ORF74. (A) Inhibition of NF- B activation.
KSIMM cells (106) were transfected with 0.3 µg of
pSG5-ORF74 and 0.5 µg of the NF- B luciferase reporter plasmid.
Cells were treated with the PI 3-kinase inhibitors LY294002 (LY) (40 µM) and wortmannin (Wt) (20 nM) or by the p38 inhibitor SB203580 (SB)
(10 µM) in dimethyl sulfoxide (DMSO) for 12 h and then assayed
for luciferase activity as described in Materials and Methods. Controls
were treated with DMSO alone. Alternatively, cells were cotransfected
with ORF74-pSG5 and 0.2 µg of DN Akt mutant expression construct or a
control plasmid and then assayed for luciferase activity as described
above. All samples were analyzed in triplicate, and the values were
averaged. Data are presented as the percent inhibition of NF- B
activity induced by ORF74 as assayed by measuring luciferase activity.
(B) Akt phosphorylation. Cell lysates from KSIMM cells transfected with
pSG5 or ORF74-pSG5 were subjected to SDS-PAGE and Western blot analysis
using an antibody specific for phosphorylated Akt (p-AKT). Lysates from
cells transfected with ORF74 and treated with the PI 3-kinase inhibitor
LY294002 (40 µM) were also analyzed. Blots were stripped and reprobed
with an antibody to total Akt (AKT) to determine the relative
phosphorylation levels. The transfection efficiencies were ca. 25%.
|
|
CM from ORF74-expressing cells activates NF-
B in ORF74-negative
cells and also induces T-cell and monocyte chemotaxis.
We next
investigated whether ORF74 expression in cells could result in the
release of soluble factors that could activate NF-
B in
ORF74-negative cells in trans. We transfected KSIMM cells with an NF-
B luciferase reporter construct and subsequently treated these target cells with conditioned medium (CM) from cells transfected with pSG5-ORF74 or pSG5 alone at 24 h posttransfection. Figure 9 shows that activation of NF-
B in
target cells by ORF74 CM was nearly threefold greater than that
obtained with CM medim from cells transfected with the control vector.
To further analyze the effects of CM from KSIMM cells expressing ORF74
on neighboring cells, we tested its ability to elicit chemotaxis of
U937 monocytoid cells and Jurkat CD4+ T cells.
Figure 10 shows that CM from
ORF74-transfected KSIMM cells indeed elicits chemotaxis of U937 cells
and, to a lesser extent, of Jurkat cells.

View larger version (10K):
[in this window]
[in a new window]
|
FIG. 9.
Paracrine stimulation of NF- B by CM from cells
transfected with ORF74. KSIMM cells (106) were transfected
with ORF74-pSG5 or pSG5. CM from these cells was collected at 24 h
posttransfection. Equal numbers of KSIMM target cells transfected with
an NF- B reporter plasmid were suspended in dilutions of 10, 25, and
50% CM in fresh medium, cultured for 6 h, and harvested.
Luciferase activity was assayed as described in Materials and Methods.
Datum points are the average of triplicate results from three wells.
|
|

View larger version (9K):
[in this window]
[in a new window]
|
FIG. 10.
Chemotaxis of U937 and Jurkat cells to CM from KSIMM
cells transfected with ORF74. CM from KSIMM cells transfected with
ORF74-pSG5 or pSG5 was collected at 24 h posttransfection.
Chemotaxis assays with the Jurkat CD4+ T-lymphoid cell
lines (A) and U937 monocytoid cells (B) were performed as described in
Materials and Methods using the indicated concentrations of CM. The
number of cells was calculated from fluorescence of calcein-labeled
cells in the lower chamber by comparison with a standard curve.
|
|
ORF74 induces the expression of NF-
B-dependent chemokines and
cytokines: IL-6, IL-8, GM-CSF, and RANTES.
Inflammation is thought
to play a key role in the development of KS, and inflammatory growth
factors and cytokines such as gamma interferon are present in KS
lesions (22). NF-
B activation is critical for the
transcription of genes involved in inflammatory responses, including
those encoding TNF-
, RANTES, IL-1
, IL-1
, IL-2, IL-6, IL-8,
IL-12, GM-CSF, granulocyte colony-stimulating factor (G-CSF) cell
adhesion molecules, acute-phase proteins, and transcription factors
such as p53 and c-myc. To determine whether ORF74 enhances the
expression of inflammatory cytokines and chemokines regulated by
NF-
B, we tested the cytokine levels in supernatants from transfected
cells. Table 1 shows that the levels of
IL-6, IL-8, and RANTES are all increased in supernatants of HUVECs and
KSIMM cells expressing ORF74. GM-CSF expression was increased by ORF74
expression in KSIMM cells but not in HUVECs. To verify that ORF74
caused the upregulation of cytokines through an NF-
B-dependent
mechanism, we cotransfected ORF74-pSG5 and the DN I
B
mutant into
KSIMM cells. The increases in IL-6, IL-8, and RANTES were reduced 60, 30, and 40%, respectively, although GM-CSF expression was not
significantly inhibited (not shown). TNF-
, IL-1
, IL-1
, IL-2,
IL-6, IL-8, IL-12, and G-CSF were not changed upon expression of ORF74
in HUVECs or KSIMM (data not shown).
ORF74 induces the expression of NF-
B-dependent adhesion
molecules VCAM-1, ICAM-1, and E-selectin.
We sought to determine
by flow cytometry whether ORF74 enhances the expression of
NF-
B-dependent adhesion molecules. Cell surface levels of VCAM-1,
ICAM-1, and, to a lesser degree, E-selectin were enhanced on KSIMM
cells expressing ORF74 (Fig. 11A, B,
and C). To ensure that ORF74 expression did not affect all cell surface markers, transfected cells were also stained with antibody against
V
3, the vitronectin receptor. Figure 11D demonstrates no
appreciable change in the surface expression of
V
3 in cells
expressing ORF74.

View larger version (44K):
[in this window]
[in a new window]
|
FIG. 11.
Induction of adhesion molecule expression by ORF74.
KSIMM cells were transfected with pSG5-ORF74 or pSG5 alone. Cells were
detached at 20 h posttransfection with 1 mM EDTA and counted.
Aliquots (0.5 × 106) of transfected cells were
stained with the indicated antibodies. Cells treated with TNF- (5 ng/ml) were included as a positive control for the induction of
adhesion marker expression (data not shown). Samples were analyzed
using a Becton Dickinson FACSCalibur flow cytometer. PE-conjugated
antibodies for VCAM-1, ICAM-1, E-selectin, and V 3 integrin were
obtained from PharMingen. Appropriate isotype-matched controls were
used for each antibody as a control for nonspecific antibody binding.
Cell Quest Analysis (Becton Dickinson version 3.1f) software was used
to analyze the raw fluorescence-activated cell-sorting data and obtain
quantitative values. (A) Analysis of expression of cell surface ICAM-1.
(B) Analysis of expression of cell surface VCAM-1. (C) Analysis of
expression of cell surface E-selectin. (D) Analysis of expression of
cell surface V 3. The solid line represents the isotype control,
the dotted line represents pSG5-transfected cells, and the dashed line
represents ORF74-transfected cells. The transfection efficiency was ca.
35%.
|
|
 |
DISCUSSION |
Infection with HHV-8 is required for the development of
KS. Previous studies have indicated that inflammatory cytokines and chemokines contribute to the development of KS (20), at
least in part by stimulating the angioproliferation and immune cell infiltration characteristic of KS lesions. Since expression of many of
these inflammatory factors is dependent on the transcription factor
NF-
B, we sought to determine whether the HHV-8 chemokine receptor
gene ORF74 could activate NF-
B and thereby induce elevated expression levels of factors that could contribute to the development of KS by paracrine mechanisms. We wanted to carry out these studies in
a relevant cell type, so we used KSIMM (an HHV-8-negative KS endothelial cell line) (2) and primary human endothelial
cells (HUVECs and dMVECs).
Our studies indicate that ORF74 indeed activates NF-
B in both KS and
primary endothelial cells, in a ligand-independent fashion. Expression
of ORF74 in KSIMM cells transactivated an NF-
B-dependent promoter
and induced DNA binding to NF-
B sites, as judged by luciferase
reporter gene activity, gel shift assays, and an ELISA-based DNA
binding assay. Activation of NF-
B by other G protein-coupled receptors (GPCR) has recently been demonstrated, although the exact
mechanisms have not fully been elucidated (45). It is clear, however, that there is a significant amount of cross talk between signaling pathways, and activation of NF-
B by chemokine receptors may be more common than is currently appreciated.
Upon transfection of lower amounts of plasmid DNA, NF-
B activation
occurred rapidly, reached a maximum by 24 h, and then diminished
and disappeared by 72 h. This activation correlated directly with
expression of ORF74 protein. Transfection of higher levels of ORF74
plasmid DNA resulted in maintenance of NF-
B activation at up to
72 h posttransfection, although it was slightly diminished from
its maximum at 24 h, and protein expression was also maintained. We do not know why the expression of ORF74 diminishes so rapidly. There
are a number of possibilities, one being that expression is toxic,
although we did not see an increase in cell death in ORF74-transfected
KSIMM cells. Toxicity of ORF74 would not be disadvantageous to virus
replication, since cells normally die during lytic phase. In the
retrovirus-infected endothelial cells, ORF74 expression is present and
does not seem to be toxic to the cells. This may be because ORF74 is
expressed at lower levels by the Moloney murine leukemia virus promoter
than by the simian virus 40 promoter. It also may be possible that even
though we did not note an increase in cell death in the samples
transfected with ORF74, untransfected cells have a growth advantage
over the transfected cells, resulting in an overall decrease in ORF74
levels. The decrease seems too fast, however, for this to be a
reasonable explanation.
The IL-8 receptor CXCR2 is the closest cellular homologue to ORF74,
suggesting that ORF74 may be a captured CXCR1 or CXCR2 gene. Among
chemokine receptors, a DRY motif in the second intracellular loop is
highly conserved. Burger et al. (10) exchanged Val for Asp
to change the DRY of CXCR2 to the VRY found in ORF74 and showed that
this resulted in a ligand-independent active receptor with transforming
potential. We performed the reverse mutagenesis, changing the VRY motif
in ORF74 to DRY, to see if it would abrogate ligand-independent
activation of NF-
B. This same mutation has recently been reported
elsewhere to not alter ligand binding or basal inducible signaling
through phospholipase C (59). The V142D mutation did not
abrogate constitutive activation of NF-
B; it slightly enhanced it.
There was an increased induction of NF-
B signaling, however, after
binding of Gro
to the mutant ORF74 compared to the wild type. Recent
work (34) confirms that the V142D mutation does not
inhibit ligand- independent signaling by ORF74 but rather enhances it.
These findings suggest that other differences between cellular
chemokine receptors and ORF74 influence ligand-independent signaling
and that different domains of ORF74 are involved in Gro
stimulation
of NF-
B and phospholipase C activation.
The multisubunit I
B kinase (IKK) is responsible for inducible
phosphorylation of I
B and appears to be the point of convergence for
most stimuli that activate NF-
B. This apparently includes ORF74
signaling. IKK
and IKK
are the two catalytic subunits of the IKK
complex, and both phosphorylate I
B. Gene knockout studies of these
kinases indicate that IKK
is primarily responsible for the
activation of NF-
B in response to proinflammatory stimuli, whereas
IKK
may not be as critical (42, 43). DN mutants of IKK
and I
B
completely inhibited NF-
B activation by ORF74 in KSIMM cells, whereas DN IKK
only partially inhibited activation under the same conditions. This pattern is similar to what would be
seen in the case of NF-
B activation by proinflammatory stimuli such
as TNF-
and suggests that ORF74 activates related pathways.
Two specific inhibitors of PI 3-kinase, LY294002 and wortmannin, almost
completely inhibited activation of NF-
B by ORF74. PI 3-kinase has
been implicated in a number of cellular functions, including cell
adhesion, vesicular trafficking, protein synthesis, and cell survival.
GPCRs, including the IL-8 receptor, have been shown to activate PI
3-kinase and its downstream target kinase Akt through G-protein
-
dimers (49, 66). The serine-threonine kinase Akt itself
has been shown to control cell survival, glycogen metabolism, and
cellular transformation (24). Recent work by other groups
has demonstrated NF-
B to be a target of Akt activation by
stimulators such as TNF-
and PDGF (58). Our findings
suggest that ORF74 indeed activates the PI 3-kinase/Akt/NF-
B
pathway. It appears from our results with LY294002 and wortmannin that this pathway is the major contributory pathway leading to activation of
NF-
B by ORF74. This would also be consistent with what has been
reported for other GPCRs and activation of NF-
B. We cannot completely rule out the possibility of other contributory pathways feeding into the activation of NF-
B, such as the MAP kinase
pathways, since there is a large degree of cross talk between pathways. The PI 3-kinase/Akt pathway may contribute significantly to the enhancement of angiogenesis and VEGF production induced by ORF74 in KS,
since recent findings have shown that PI 3-kinase/Akt signaling mediates angiogenesis and the expression of VEGF in endothelial cells
(35). We find that treatment of KSIMM cells with the PI 3-kinase inhibitor LY294002 suppresses the increase in VEGF production by ORF74 (data not shown), suggesting that ORF74 utilizes pathways in
addition to the p38 MAP kinase pathway to upregulate VEGF
(62).
In spite of the strong epidemiologic association of HHV-8 with KS, it
is not clear how the virus initiates or facilitates the disease. As
mentioned previously, in early KS lesions, only a minority of the
spindle cells believed to constitute the abnormal cell population are
infected (8). In later lesions, although most spindle
cells are infected, the majority of infected cells are in viral
latency, and only a few cells are undergoing lytic replication
(8, 64). Infection of a minority of primary endothelial cells has been reported to transform the culture as a whole
(23). Recently, transgenic mice expressing ORF74 in
hematopoietic cells have been shown to develop angioproliferative
lesions in the skin that display many characteristics of KS, suggesting
a paracrine pathogenic mechanism of ORF74 (69) that the
authors of that study attribute primarily to the induction of VEGF expression.
We found that CM from KSIMM cells transfected with ORF74 is capable of
activating NF-
B in cells not expressing ORF74, suggesting that a
minority of cells in KS lesions expressing ORF74 could affect the
proliferation and activation of neighboring cells through the release
of soluble factors. The finding that CM from cells transfected with
ORF74 can itself activate NF-
B suggests that part of the NF-
B
activity that we see in ORF74-transfected KSIMM cells could be by a
paracrine mechanism. It is difficult to discriminate between a direct
effect and a paracrine effect, although the rapidity of induction of
luciferase activity and NF-
B binding to oligonucleotides argues that
in this system much of the activation by ORF74 is direct. The same CM
was also able to elicit enhanced chemotaxis of immune cells (U937 cells
and, to a lesser extent, Jurkat cells), suggesting that ORF74 may
contribute to the characteristic immune cell infiltration of KS
lesions. Analysis of this CM showed elevated levels of
NF-
B-dependent chemokines and cytokines, including IL-6, IL-8,
GM-CSF, and RANTES. Increases were similar with both KSIMM CM and HUVEC
CM, except for GM-CSF, which was increased only in KSIMM CM. The
contribution of NF-
B to the increases in these cytokines and
chemokines by ORF74 was evident from the partial inhibition of these
increases by cotransfection of a DN mutant of I
B
. There was also
an induction in VEGF expression by ORF74, as reported by other groups
(5, 62). The most striking ORF74-induced increase was in
RANTES, which increased 14- and 9-fold in HUVECs and KSIMM,
respectively. RANTES could contribute to enhanced chemotaxis toward KS
cells expressing ORF74. It is possible, however, that many of these
factors cooperate in producing the angioproliferation and inflammation
seen in KS lesions. IL-8 is an
chemokine that is chemotactic for
lymphocytes and neutrophils and has been shown to be proangiogenic
through its ability to stimulate the proliferation, migration, and
chemotaxis of endothelial cells (39). IL-6 has also been
implicated in angiogenesis and has been shown to induce expression of
VEGF in endothelial cells (17, 48). GM-CSF can also
enhance the migration and proliferation of human endothelial cells
(13). These findings suggest that ORF74 helps to
upregulate the production of a number of proangiogenic, inflammatory
factors, in addition to VEGF, which all may contribute significantly to the development of KS by both paracrine and autocrine mechanisms.
As mentioned previously, KS lesions are composed of a complex mixture
of different cell types, including not only the characteristic spindle
cells but also fibroblasts, microvascular endothelial cells, dendritic
cells, and a prominent infiltrate of extravasated erythrocytes and
lymphocytes. Recently, expression on KS cells of adhesion molecules
known to be involved in endothelial cell-leukocyte interactions has
been reported to contribute to the extravasation of leukocytes into the
lesions (25). During tissue inflammation, normal
endothelial cells can be induced to become adhesive for circulating
blood cells and to support their transmigration into inflamed tissue.
Much of this process is mediated by adhesion molecules expressed on
either lymphocytes or endothelium under regulation by NF-
B. Galea et
al. (25) have shown that the LFA1-ICAM-1 interaction is
the primary one involved in the adhesion of peripheral blood
lymphocytes to KSY1 cells (another KS cell line). We find that ORF74
upregulates the expression of VCAM-1, ICAM-1, and E-selectin on KSIMM
cells, with the most significant increase in ICAM-1. It is worth noting
that the fraction of cells expressing ICAM-1 (100%) exceeds the
fraction of cells that we estimate are transfected (30%). Expression
of ICAM-1 by cells not expressing ORF74 could occur by induction of
expression of soluble factors by ORF74 or could be due to physical
contact with cells expressing ORF74.
Although the cell of origin of KS is a source of controversy,
phenotypic characterization and electron microscopic analyses of the
long-term-cultured cells such as KSIMM indicate an endothelial cell
origin (67). Several in vitro studies have shown that
normal endothelial cells can be induced to acquire a typical spindle morphology by cytokines or the HIV-1 Tat protein (21). In
our studies, HUVECs and dMVECs transduced with a retroviral vector expressing ORF74 adopted a spindle-shaped morphology strikingly similar
to that of the spindle-shaped cells found in KS lesions.
NF-
B regulates the transcription of an exceptionally large number of
genes, particularly many that participate in immune and inflammatory
responses. Inappropriate regulation of NF-
B contributes to a wide
range of disorders, including cancer and numerous other inflammatory
conditions. Recently, Keller et al. have demonstrated that the
inhibition of NF-
B induces apoptosis in HHV-8-infected primary
effusion lymphoma cells, suggesting that NF-
B is necessary for their
survival (36). NF-
B activation also functions in the
antiviral response through regulation of interferon expression
(63). However, many viruses, including HIV-1 and human
T-cell leukemia virus type 1, exploit NF-
B to activate their own
genes and to stimulate the survival and proliferation of the cells in
which they replicate. HHV-8, via genes such as ORF74, appears to have
also exploited these pathways to promote its own survival and propagation.
We have shown that expression of a single gene of HHV-8, ORF74, is
capable of affecting neighboring cells through induction of expression
of a variety of soluble proinflammatory factors. These may contribute
substantially to the development of KS via paracrine mechanisms. The
induction appears to be mediated at least in part by the
ligand-independent activation of NF-
B signaling pathways by ORF74.
These findings suggest a way in which the minority of cells in lesions
in which HHV-8 lytic-phase replication is occurring may be able to
influence the biology of the lesions as a whole.
 |
ACKNOWLEDGMENTS |
This work was supported by NCI grants P01 CA78817 to M.R. and RO1
CA55293 to R.A.F. S. Pati was supported by a predoctoral training
grant from the National Cancer Center.
We thank Gary Hayward from Johns Hopkins University for the generous
gift of antibody against ORF74. We also gratefully acknowledge the
editorial assistance of Paula Dean.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Institute of
Human Virology, University of Maryland, 725 W. Lombard St., Baltimore, MD 21201. Phone: (410) 708-4679. Fax: (410) 706-4694. E-mail: reitz{at}umbi.umd.edu.
 |
REFERENCES |
| 1.
|
Ablashi, D.,
L. Chatlynne,
H. Cooper,
D. Thomas,
M. Yadav,
A. W. Norhanom,
A. K. Chandana,
V. Churdboonchart,
S. A. R. Kulpradist,
M. Patnaik,
K. Liegmann,
R. Masood,
M. Reitz,
F. Cleghorn,
A. Manns,
P. H. Levine,
C. Rabkin,
R. Biggar,
F. Jensen,
P. Gill,
N. Jack,
J. Edwards,
J. Whitman, and C. Boshoff.
1999.
Seroprevalence of human herpesvirus-8 (HHV-8) in countries of Southeast Asia compared to the USA, the Caribbean and Africa.
Br. J. Cancer
81:893-897[CrossRef][Medline].
|
| 2.
|
Albini, A.,
I. Paglieri,
G. Orengo,
S. Carlone,
M. G. Aluigi,
R. DeMarchi,
C. Matteucci,
A. Mantovani,
F. Carozzi,
S. Donini, and R. Benelli.
1997.
The beta-core fragment of human chorionic gonadotrophin inhibits growth of Kaposi's sarcoma-derived cells and a new immortalized Kaposi's sarcoma cell line.
AIDS
11:713-721[CrossRef][Medline].
|
| 3.
|
Ariyoshi, K.,
M. S. van der Loeff,
P. Cook,
D. Whitby,
T. Corrah,
S. Jaffar,
F. Cham,
S. Sabally,
D. O'Donovan,
R. A. Weiss,
T. F. Schulz, and H. Whittle.
1998.
Kaposi's sarcoma in the Gambia, West Africa is less frequent in human immunodeficiency virus type 2 than in human immunodeficiency virus type 1 infection despite a high prevalence of human herpesvirus 8.
J. Hum. Virol.
1:193-199[Medline].
|
| 4.
|
Arvanitakis, L.,
E. Geras-Raaka,
A. Varma,
M. C. Gershengorn, and E. Cesarman.
1997.
Human herpesvirus KSHV encodes a constitutively active G-protein-coupled receptor linked to cell proliferation.
Nature
385:347-350[CrossRef][Medline].
|
| 5.
|
Bais, C.,
B. Santomasso,
O. Coso,
L. Arvanitakis,
E. G. Raaka,
J. S. Gutkind,
A. S. Asch,
E. Cesarman,
M. C. Gershengorn, and E. A. Mesri.
1998.
G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator.
Nature
391:86-89[CrossRef][Medline]. (Erratum, 392:210.)
|
| 6.
|
Biggar, R. J., and C. S. Rabkin.
1996.
The epidemiology of AIDS-related neoplasms.
Hematol. Oncol. Clin. N. Am.
10:997-1010[CrossRef][Medline].
|
| 7.
|
Biggar, R. J.,
P. S. Rosenberg, and T. Cote.
1996.
Kaposi's sarcoma and non-Hodgkin's lymphoma following the diagnosis of AIDS. Multistate AIDS/Cancer Match Study Group.
Int. J. Cancer
68:754-758[CrossRef][Medline].
|
| 8.
|
Blasig, C.,
C. Zietz,
B. Haar,
F. Neipel,
S. Esser,
N. H. Brockmeyer,
E. Tschachler,
S. Colombini,
B. Ensoli, and M. Sturzl.
1997.
Monocytes in Kaposi's sarcoma lesions are productively infected by human herpesvirus 8.
J. Virol.
71:7963-7968[Abstract].
|
| 9.
|
Boshoff, C.,
Y. Endo,
P. D. Collins,
Y. Takeuchi,
J. D. Reeves,
V. L. Schweickart,
M. A. Siani,
T. Sasaki,
T. J. Williams,
P. W. Gray,
P. S. Moore,
Y. Chang, and R. A. Weiss.
1997.
Angiogenic and HIV-inhibitory functions of KSHV-encoded chemokines.
Science
278:290-294[Abstract/Free Full Text].
|
| 10.
|
Burger, M.,
J. A. Burger,
R. C. Hoch,
Z. Oades,
H. Takamori, and I. U. Schraufstatter.
1999.
Point mutation causing constitutive signaling of CXCR2 leads to transforming activity similar to Kaposi's sarcoma herpesvirus-G protein-coupled receptor.
J. Immunol.
163:2017-2022[Abstract/Free Full Text].
|
| 11.
|
Burns, J. M., and G. K. Lewis.
1998.
Improved measurements of calcium mobilization by flow cytometry.
BioTechniques
23:1022-1023.
|
| 12.
|
Burysek, L.,
W. S. Yeow, and P. M. Pitha.
1999.
Unique properties of a second human herpesvirus 8-encoded interferon regulatory factor (vIRF-2).
J. Hum. Virol.
2:19-32[Medline].
|
| 13.
|
Bussolino, F.,
J. M. Wang,
P. Defilippi,
F. Turrini,
F. Sanavio,
C. J. Edgell,
M. Aglietta,
P. Arese, and A. Mantovani.
1989.
Granulocyte- and granulocyte-macrophage-colony stimulating factors induce human endothelial cells to migrate and proliferate.
Nature
337:471-473[CrossRef][Medline].
|
| 14.
|
Cesarman, E.,
Y. Chang,
P. S. Moore,
J. W. Said, and D. M. Knowles.
1995.
Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas.
N. Engl. J. Med.
332:1186-1191[Abstract/Free Full Text].
|
| 15.
|
Cesarman, E.,
E. A. Mesri, and M. C. Gershengorn.
2000.
Viral G protein-coupled receptor and Kaposi's sarcoma: a model of paracrine neoplasia?
J. Exp. Med.
191:417-422[Free Full Text].
|
| 16.
|
Chang, Y.,
E. Cesarman,
M. S. Pessin,
F. Lee,
J. Culpepper,
D. M. Knowles, and P. S. Moore.
1994.
Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma.
Science
266:1865-1869[Abstract/Free Full Text].
|
| 17.
|
Cohen, T.,
D. Nahari,
L. W. Cerem,
G. Neufeld, and B. Z. Levi.
1996.
Interleukin 6 induces the expression of vascular endothelial growth factor.
J. Biol. Chem.
271:736-741[Abstract/Free Full Text].
|
| 18.
|
DiDonato, J.,
F. Mercurio,
C. Rosette,
J. Wu-Li,
H. Suyang,
S. Ghosh, and M. Karin.
1996.
Mapping of the inducible I B phosphorylation sites that signal its ubiquitination and degradation.
Mol. Cell. Biol.
16:1295-1304[Abstract].
|
| 19.
|
Dudek, H.,
S. R. Datta,
T. F. Franke,
M. J. Birnbaum,
R. Yao,
G. M. Cooper,
R. A. Segal,
D. R. Kaplan, and M. E. Greenberg.
1997.
Regulation of neuronal survival by the serine-threonine protein kinase Akt.
Science
275:661-665[Abstract/Free Full Text].
|
| 20.
|
Ensoli, B.,
G. Barillari, and R. C. Gallo.
1992.
Cytokines and growth factors in the pathogenesis of AIDS-associated Kaposi's sarcoma.
Immunol. Rev.
127:147-155[CrossRef][Medline].
|
| 21.
|
Fiorelli, V.,
R. Gendelman,
F. Samaniego,
P. D. Markham, and B. Ensoli.
1995.
Cytokines from activated T cells induce normal endothelial cells to acquire the phenotypic and functional features of AIDS-Kaposi's sarcoma spindle cells.
J. Clin. Investig.
95:1723-1734.
|
| 22.
|
Fiorelli, V.,
R. Gendelman,
M. C. Sirianni,
H. K. Chang,
S. Colombini,
P. D. Markham,
P. Monini,
J. Sonnabend,
A. Pintus,
R. C. Gallo, and B. Ensoli.
1998.
-Interferon produced by CD8+ T cells infiltrating Kaposi's sarcoma induces spindle cells with angiogenic phenotype and synergy with human immunodeficiency virus-1 Tat protein: an immune response to human herpesvirus-8 infection?
Blood
91:956-967[Abstract/Free Full Text].
|
| 23.
|
Flore, O.,
S. Rafii,
S. Ely,
J. J. O'Leary,
E. M. Hyjek, and E. Cesarman.
1998.
Transformation of primary human endothelial cells by Kaposi's sarcoma-associated herpesvirus.
Nature
394:588-592[CrossRef][Medline].
|
| 24.
|
Franke, T. F.,
D. R. Kaplan, and L. C. Cantley.
1997.
PI3K: downstream AKTion blocks apoptosis.
Cell
88:435-437[CrossRef][Medline].
|
| 25.
|
Galea, P.,
V. Frances,
L. Dou-Dameche,
J. Sampol, and J. C. Chermann.
1998.
Role of Kaposi's sarcoma cells in recruitment of circulating leukocytes: implications in pathogenesis.
J. Hum. Virol.
1:273-281[Medline].
|
| 26.
|
Gao, S. J.,
C. Boshoff,
S. Jayachandra,
R. A. Weiss,
Y. Chang, and P. S. Moore.
1997.
KSHV ORF K9 (vIRF) is an oncogene which inhibits the interferon signaling pathway.
Oncogene
15:1979-1985[CrossRef][Medline].
|
| 27.
|
Gao, S. J.,
L. Kingsley,
D. R. Hoover,
T. J. Spira,
C. R. Rinaldo,
A. Saah,
J. Phair,
R. Detels,
P. Parry,
Y. Chang, and P. S. Moore.
1996.
Seroconversion to antibodies against Kaposi's sarcoma-associated herpesvirus-related latent nuclear antigens before the development of Kaposi's sarcoma.
N. Engl. J. Med.
335:233-241[Abstract/Free Full Text].
|
| 28.
|
Gao, S. J.,
L. Kingsley,
M. Li,
W. Zheng,
C. Parravicini,
J. Ziegler,
R. Newton,
C. R. Rinaldo,
A. Saah,
J. Phair,
R. Detels,
Y. Chang, and P. S. Moore.
1996.
KSHV antibodies among Americans, Italians and Ugandans with and without Kaposi's sarcoma.
Nat. Med.
2:925-928[CrossRef][Medline].
|
| 29.
|
Geras-Raaka, E.,
A. Varma,
I. Clark-Lewis, and M. C. Gershengorn.
1998.
Kaposi's sarcoma-associated herpesvirus (KSHV) chemokine vMIP-II and human SDF-1alpha inhibit signaling by KSHV G protein-coupled receptor.
Biochem. Biophys. Res. Commun.
253:725-727[CrossRef][Medline].
|
| 30.
|
Geras-Raaka, E.,
A. Varma,
H. Ho,
I. Clark-Lewis, and M. C. Gershengorn.
1998.
Human interferon-gamma-inducible protein 10 (IP-10) inhibits constitutive signaling of Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor.
J. Exp. Med.
188:405-408[Abstract/Free Full Text].
|
| 31.
|
Gershengorn, M. C.,
E. Geras-Raaka,
A. Varma, and I. Clark-Lewis.
1998.
Chemokines activate Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor in mammalian cells in culture.
J. Clin. Investig.
102:1469-1472[Medline].
|
| 32.
|
Glenn, M.,
L. Rainbow,
F. Aurade,
A. Davison, and T. F. Schulz.
1999.
Identification of a spliced gene from Kaposi's sarcoma-associated herpesvirus encoding a protein with similarities to latent membrane proteins 1 and 2A of Epstein-Barr virus.
J. Virol.
73:6953-6963[Abstract/Free Full Text].
|
| 33.
|
Guo, H.-G.,
P. Browning,
J. Nicholas,
G. S. Hayward,
E. Tschachler,
Y. W. Jiang,
M. Sadowska,
M. Raffeld,
S. Colombini,
R. C. Gallo, and M. S. Reitz.
1997.
Characterization of a chemokine receptor-related gene in human herpesvirus 8 and its expression in Kaposi's sarcoma.
Virology
228:371-378[CrossRef][Medline].
|
| 34.
|
Ho, H. H.,
N. Ganeshalingam,
A. Rosenhouse-Dantsker,
R. Osman, and M. C. Gershengorn.
2001.
Charged residues at the intracellular boundary of transmembrane helices 2 and 3 independently affect constitutive activity of Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor.
J. Biol. Chem.
276:1376-1382[Abstract/Free Full Text].
|
| 35.
|
Jiang, B. H.,
J. Z. Zheng,
M. Aoki, and P. K. Vogt.
2000.
Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells.
Proc. Natl. Acad. Sci. USA
97:1749-1753[Abstract/Free Full Text].
|
| 36.
|
Keller, S. A.,
E. J. Schattner, and E. Cesarman.
2000.
Inhibition of NF- B induces apoptosis of KSHV-infected primary effusion lymphoma cells.
Blood
96:2537-2542[Abstract/Free Full Text].
|
| 37.
|
Kirshner, J. R.,
K. Staskus,
A. Haase,
M. Lagunoff, and D. Ganem.
1999.
Expression of the open reading frame 74 (G-protein-coupled receptor) gene of Kaposi's sarcoma (KS)-associated herpesvirus: implications for KS pathogenesis.
J. Virol.
73:6006-6014[Abstract/Free Full Text].
|
| 38.
|
Kledal, T. N.,
M. M. Rosenkilde,
F. Coulin,
G. Simmons,
A. H. Johnsen,
S. Alouani,
C. A. Power,
H. R. Luttichau,
J. Gerstoft,
P. R. Clapham,
I. Clark-Lewis,
T. N. C. Wells, and T. W. Schwartz.
1997.
A broad-spectrum chemokine antagonist encoded by Kaposi's sarcoma-associated herpesvirus.
Science
277:1656-1659[Abstract/Free Full Text].
|
| 39.
|
Koch, A. E.,
P. J. Polverini,
S. L. Kunkel,
L. A. Harlow,
L. A. DiPietro,
V. M. Elner,
S. G. Elner, and R. M. Strieter.
1992.
Interleukin-8 as a macrophage-derived mediator of angiogenesis.
Science
258:1798-1801[Abstract/Free Full Text].
|
| 40.
|
Lee, H.,
J. Guo,
M. Li,
J. K. Choi,
M. DeMaria,
M. Rosenzweig, and J. U. Jung.
1998.
Identification of an immunoreceptor tyrosine-based activation motif of K1 transforming protein of Kaposi's sarcoma-associated herpesvirus.
Mol. Cell. Biol.
18:5219-5228[Abstract/Free Full Text].
|
| 41.
|
Lefrere, J. J.,
M. C. Meyohas,
M. Mariotti,
J. L. Meynard,
M. Thauvin, and J. Frottier.
1996.
Detection of human herpesvirus 8 DNA sequences before the appearance of Kaposi's sarcoma in human immunodeficiency virus (HIV)-positive subjects with a known date of HIV seroconversion.
J. Infect. Dis.
174:283-287[Medline].
|
| 42.
|
Li, Q.,
Q. Lu,
J. Y. Hwang,
D. Buscher,
K. F. Lee,
J. C. Izpisua-Belmonte, and I. M. Verma.
1999.
IKK1-deficient mice exhibit abnormal development of skin and skeleton.
Genes Dev.
13:1322-1328[Abstract/Free Full Text].
|
| 43.
|
Li, Q.,
D. Van Antwerp,
F. Mercurio,
K. F. Lee, and I. M. Verma.
1999.
Severe liver degeneration in mice lacking the I B kinase 2 gene.
Science
284:321-325[Abstract/Free Full Text].
|
| 44.
|
Mayama, S.,
L. E. Cuevas,
J. Sheldon,
O. H. Omar,
D. H. Smith,
P. Okong,
B. Silvel,
C. A. Hart, and T. F. Schulz.
1998.
Prevalence and transmission of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in Ugandan children and adolescents.
Int. J. Cancer
77:817-820[CrossRef][Medline].
|
| 45.
|
Minneman, K. P.,
D. Lee,
H. Zhong,
A. Berts,
K. L. Abbott, and T. J. Murphy.
2000.
Transcriptional responses to growth factor and G protein-coupled receptors in PC12 cells: comparison of alpha(1)-adrenergic receptor subtypes.
J. Neurochem.
74:2392-2400[CrossRef][Medline].
|
| 46.
|
Moore, P. S.,
C. Boshoff,
R. A. Weiss, and Y. Chang.
1996.
Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV.
Science
274:1739-1744[Abstract/Free Full Text].
|
| 47.
|
Moore, P. S.,
L. A. Kingsley,
S. D. Holmberg,
T. J. Spira,
P. Gupta,
D. R. Hoover,
J. P. Parry,
L. J. Conley,
H. W. Jaffe, and Y. Chang.
1996.
Kaposi's sarcoma-associated herpesvirus infection prior to onset of Kaposi's sarcoma.
AIDS
10:175-180[Medline].
|
| 48.
|
Motro, B.,
A. Itin,
L. Sachs, and E. Keshet.
1990.
Pattern of interleukin 6 gene expression in vivo suggests a role for this cytokine in angiogenesis.
Proc. Natl. Acad. Sci. USA
87:3092-3096[Abstract/Free Full Text].
|
| 49.
|
Murga, C.,
L. Laguinge,
R. Wetzker,
A. Cuadrado, and J. S. Gutkind.
1998.
Activation of Akt/protein kinase B by G protein-coupled receptors. A role for alpha and beta gamma subunits of heterotrimeric G proteins acting through phosphatidylinositol-3-OH kinase gamma.
J. Biol. Chem.
273:19080-19085[Abstract/Free Full Text].
|
| 50.
|
Neipel, F.,
J.-C. Albrecht,
A. Ensser,
Y. Q. Huang,
J. J. Li,
A. E. Friedman-Kien, and B. Fleckenstein.
1997.
Human herpesvirus 8 encodes a homolog of interleukin-6.
J. Virol.
71:839-842[Abstract].
|
| 51.
|
Nicholas, J.,
V. Ruvolo,
W. H. Burns,
G. Sandford,
X. Wan,
D. Ciufo,
S. B. Hendrickson,
H.-G. Guo,
G. S. Hayward, and M. S. Reitz.
1997.
Kaposi's sarcoma-associated human herpesvirus-8 encodes homologues of macrophage inflammatory protein-1 and interleukin-6.
Nat. Med.
3:287-292[CrossRef][Medline].
|
| 52.
|
Ozes, O. N.,
L. D. Mayo,
J. A. Gustin,
S. R. Pfeffer,
L. M. Pfeffer, and D. B. Donner.
1999.
NF- B activation by tumour necrosis factor requires the Akt serine-threonine kinase.
Nature
401:82-85[CrossRef][Medline].
|
| 53.
|
Pear, W. S.,
J. P. Miller,
L. Xu,
J. C. Pui,
B. Soffer,
R. C. Quackenbush,
A. M. Pendergast,
R. Bronson,
J. C. Aster,
M. L. Scott, and D. Baltimore.
1998.
Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow.
Blood
92:3780-3792[Abstract/Free Full Text].
|
| 54.
|
Poole, L. J.,
J. C. Zong,
D. M. Ciufo,
D. J. Alcendor,
J. S. Cannon,
R. Ambinder,
J. M. Orenstein,
M. S. Reitz, and G. S. Hayward.
1999.
Comparison of genetic variability at multiple loci across the genomes of the major subtypes of Kaposi's sarcoma-associated herpesvirus reveals evidence for recombination and for two distinct types of open reading frame K15 alleles at the right-hand end.
J. Virol.
73:6646-6660[Abstract/Free Full Text].
|
| 55.
|
Rabkin, C. S.,
R. J. Biggar,
M. S. Baptiste,
T. Abe,
B. A. Kohler, and P. C. Nasca.
1993.
Cancer incidence trends in women at high risk of human immunodeficiency virus (HIV) infection.
Int. J. Cancer
55:208-212[Medline].
|
| 56.
|
Renard, P.,
I. Ernest,
A. Houbion,
M. Art,
H. Le Calvez,
M. Raes, and J. Remacle.
2001.
Development of a sensitive multi-well colorimetric assay for active NF B.
Nucleic Acids Res.
29:E21.
|
| 57.
|
Renwick, N.,
T. Halaby,
G. J. Weverling,
N. H. Dukers,
G. R. Simpson,
R. A. Coutinho,
J. M. Lange,
T. F. Schulz, and J. Goudsmit.
1998.
Seroconversion for human herpesvirus 8 during HIV infection is highly predictive of Kaposi's sarcoma.
AIDS
12:2481-2488[CrossRef][Medline].
|
| 58.
|
Romashkova, J. A., and S. S. Makarov.
1999.
NF- B is a target of AKT in anti-apoptotic PDGF signaling.
Nature
401:86-90[CrossRef][Medline].
|
| 59.
|
Rosenkilde, M. M.,
T. N. Kledal,
P. J. Holst, and T. W. Schwartz.
2000.
Selective elimination of high constitutive activity or chemokine binding in the human herpesvirus 8 encoded seven transmembrane oncogene ORF74.
J. Biol. Chem.
275:26309-26315[Abstract/Free Full Text].
|
| 60.
|
Sarid, R.,
O. Flore,
R. A. Bohenzky,
Y. Chang, and P. S. Moore.
1998.
Transcription mapping of the Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) genome in a body cavity-based lymphoma cell line (BC-1).
J. Virol.
72:1005-1012[Abstract/Free Full Text].
|
| 61.
|
Simpson, G. R.,
T. F. Schulz,
D. Whitby,
P. M. Cook,
C. Boshoff,
L. Rainbow,
M. R. Howard,
S. J. Gao,
R. A. Bohenzky,
P. Simmonds,
C. Lee,
A. de Ruiter,
A. Hatzakis,
R. S. Tedder,
I. V. Weller,
R. A. Weiss, and P. S. Moore.
1996.
Prevalence of Kaposi's sarcoma associated herpesvirus infection measured by antibodies to recombinant capsid protein and latent immunofluorescence antigen.
Lancet
348:1133-1138[CrossRef][Medline].
|
| 62.
|
Sodhi, A.,
S. Montaner,
V. Patel,
M. Zohar,
C. Bais,
E. A. Mesri, and J. S. Gutkind.
2000.
The Kaposi's sarcoma-associated herpes virus G protein-coupled receptor up-regulates vascular endothelial growth factor expression and secretion through mitogen-activated protein kinase and p38 pathways acting on hypoxia-inducible factor 1 .
Cancer Res.
60:4873-4880[Abstract/Free Full Text].
|
| 63.
|
Stark, G. R.,
I. M. Kerr,
B. R. Williams,
R. H. Silverman, and R. D. Schreiber.
1998.
How cells respond to interferons.
Annu. Rev. Biochem.
67:227-264[CrossRef][Medline].
|
| 64.
|
Staskus, K. A.,
W. Zhong,
K. Gebhard,
B. Herndier,
H. Wang,
R. Renne,
J. Beneke,
J. Pudney,
D. J. Anderson,
D. Ganem, and A. T. Haase.
1997.
Kaposi's sarcoma-associated herpesvirus gene expression in endothelial (spindle) tumor cells.
J. Virol.
71:715-719[Abstract].
|
| 65.
|
Thome, M.,
P. Schneider,
K. Hofmann,
H. Fickenscher,
E. Meinl,
F. Neipel,
C. Mattmann,
K. Burns,
J. L. Bodmer,
M. Schroter,
C. Scaffidi,
P. H. Krammer,
M. E. Peter, and J. Tschopp.
1997.
Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors.
Nature
386:517-521[CrossRef][Medline].
|
| 66.
|
Tilton, B.,
M. Andjelkovic,
S. A. Didichenko,
B. A. Hemmings, and M. Thelen.
1997.
G-protein-coupled receptors and Fc -receptors mediate activation of Akt/protein kinase B in human phagocytes.
J. Biol. Chem.
272:28096-28101[Abstract/Free Full Text].
|
| 67.
|
Uccini, S.,
L. P. Ruco,
F. Monardo,
A. Stoppacciaro,
E. Dejana,
I. L. La Parola,
D. Cerimele, and C. D. Baroni.
1994.
Co-expression of endothelial cell and macrophage antigens in Kaposi's sarcoma cells.
J. Pathol.
173:23-31[CrossRef][Medline].
|
| 68.
|
Whitby, D.,
M. R. Howard,
M. Tenant-Flowers,
N. S. Brink,
A. Copas,
C. Boshoff,
T. Hatzioannou,
F. E. Suggett,
D. M. Aldam, and A. S. Denton.
1995.
Detection of Kaposi sarcoma-associated herpesvirus in peripheral blood of HIV-infected individuals and progression to Kaposi's sarcoma.
Lancet
346:799-802[CrossRef][Medline].
|
| 69.
|
Yang, B. T.,
S. C. Chen,
M. W. Leach,
D. Manfra,
B. Homey,
M. Wiekowski,
L. Sullivan,
C. H. Jenh,
S. K. Narula,
S. W. Chensue, and S. A. Lira.
2000.
Transgenic expression of the chemokine receptor encoded by human herpesvirus 8 induces an angioproliferative disease resembling Kaposi's sarcoma.
J. Exp. Med.
191:445-454[Abstract/Free Full Text].
|
Journal of Virology, September 2001, p. 8660-8673, Vol. 75, No. 18
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.18.8660-8673.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Dela Cruz, C. S., Viswanathan, S. R., El-Guindy, A. S., Shedd, D., Miller, G.
(2009). Complex N-Linked Glycans on Asn-89 of Kaposi Sarcoma Herpes Virus-encoded Interleukin-6 Mediate Optimal Function by Affecting Cytokine Protein Conformation. J. Biol. Chem.
284: 29269-29282
[Abstract]
[Full Text]
-
Maussang, D., Vischer, H. F., Leurs, R., Smit, M. J.
(2009). Herpesvirus-Encoded G Protein-Coupled Receptors as Modulators of Cellular Function. Mol. Pharmacol.
76: 692-701
[Abstract]
[Full Text]
-
Couty, J.-P., Lupu-Meiri, M., Oron, Y., Gershengorn, M. C.
(2009). Kaposi's Sarcoma-Associated Herpesvirus-G Protein-Coupled Receptor-Expressing Endothelial Cells Exhibit Reduced Migration and Stimulated Chemotaxis by Chemokine Inverse Agonists. J. Pharmacol. Exp. Ther.
329: 1142-1147
[Abstract]
[Full Text]
-
Aggarwal, B. B., Vijayalekshmi, R.V., Sung, B.
(2009). Targeting Inflammatory Pathways for Prevention and Therapy of Cancer: Short-Term Friend, Long-Term Foe. Clin. Cancer Res.
15: 425-430
[Abstract]
[Full Text]
-
Sausville, J., Molinolo, A. A., Cheng, X., Frampton, J., Takebe, N., Gutkind, J. S., Feldman, R. A.
(2008). RCAS/SCL-TVA Animal Model Allows Targeted Delivery of Polyoma Middle T Oncogene to Vascular Endothelial Progenitors In vivo and Results in Hemangioma Development. Clin. Cancer Res.
14: 3948-3955
[Abstract]
[Full Text]
-
Efklidou, S., Bailey, R., Field, N., Noursadeghi, M., Collins, M. K.
(2008). vFLIP from KSHV inhibits anoikis of primary endothelial cells. J. Cell Sci.
121: 450-457
[Abstract]
[Full Text]
-
Sethi, G., Sung, B., Aggarwal, B. B.
(2008). Nuclear Factor-{kappa}B Activation: From Bench to Bedside. Exp. Biol. Med.
233: 21-31
[Abstract]
[Full Text]
-
Hair, J. R., Lyons, P. A., Smith, K. G. C., Efstathiou, S.
(2007). Control of Rta expression critically determines transcription of viral and cellular genes following gammaherpesvirus infection. J. Gen. Virol.
88: 1689-1697
[Abstract]
[Full Text]
-
Sadagopan, S., Sharma-Walia, N., Veettil, M. V., Raghu, H., Sivakumar, R., Bottero, V., Chandran, B.
(2007). Kaposi's Sarcoma-Associated Herpesvirus Induces Sustained NF-{kappa}B Activation during De Novo Infection of Primary Human Dermal Microvascular Endothelial Cells That Is Essential for Viral Gene Expression. J. Virol.
81: 3949-3968
[Abstract]
[Full Text]
-
Ye, F.-C., Blackbourn, D. J., Mengel, M., Xie, J.-P., Qian, L.-W., Greene, W., Yeh, I-T., Graham, D., Gao, S.-J.
(2007). Kaposi's Sarcoma-Associated Herpesvirus Promotes Angiogenesis by Inducing Angiopoietin-2 Expression via AP-1 and Ets1. J. Virol.
81: 3980-3991
[Abstract]
[Full Text]
-
Caselli, E., Fiorentini, S., Amici, C., Di Luca, D., Caruso, A., Santoro, M. G.
(2007). Human herpesvirus 8 acute infection of endothelial cells induces monocyte chemoattractant protein 1-dependent capillary-like structure formation: role of the IKK/NF-{kappa}B pathway. Blood
109: 2718-2726
[Abstract]
[Full Text]
-
Brinkmann, M. M., Pietrek, M., Dittrich-Breiholz, O., Kracht, M., Schulz, T. F.
(2007). Modulation of Host Gene Expression by the K15 Protein of Kaposi's Sarcoma-Associated Herpesvirus. J. Virol.
81: 42-58
[Abstract]
[Full Text]
-
Rezaee, S. A. R., Cunningham, C., Davison, A. J., Blackbourn, D. J.
(2006). Kaposi's sarcoma-associated herpesvirus immune modulation: an overview. J. Gen. Virol.
87: 1781-1804
[Abstract]
[Full Text]
-
Khakoo, A. Y., Pati, S., Anderson, S. A., Reid, W., Elshal, M. F., Rovira, I. I., Nguyen, A. T., Malide, D., Combs, C. A., Hall, G., Zhang, J., Raffeld, M., Rogers, T. B., Stetler-Stevenson, W., Frank, J. A., Reitz, M., Finkel, T.
(2006). Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma. JEM
203: 1235-1247
[Abstract]
[Full Text]
-
Brown, E. E., Fallin, D., Ruczinski, I., Hutchinson, A., Staats, B., Vitale, F., Lauria, C., Serraino, D., Rezza, G., Mbisa, G., Whitby, D., Messina, A., Goedert, J. J., Chanock, S. J., Kaposi Sarcoma Working Group,
(2006). Associations of Classic Kaposi Sarcoma with Common Variants in Genes that Modulate Host Immunity.. Cancer Epidemiol. Biomarkers Prev.
15: 926-934
[Abstract]
[Full Text]
-
Montaner, S., Sodhi, A., Ramsdell, A. K., Martin, D., Hu, J., Sawai, E. T., Gutkind, J. S.
(2006). The Kaposi's Sarcoma-Associated Herpesvirus G Protein-Coupled Receptor as a Therapeutic Target for the Treatment of Kaposi's Sarcoma. Cancer Res.
66: 168-174
[Abstract]
[Full Text]
-
Parsons, C. H.
(2005). Kinase Lynks to herpesvirus lymphomagenesis. Blood
105: 3762-3762
[Full Text]
-
Prakash, O., Swamy, O. R., Peng, X., Tang, Z.-Y., Li, L., Larson, J. E., Cohen, J. C., Gill, J., Farr, G., Wang, S., Samaniego, F.
(2005). Activation of Src kinase Lyn by the Kaposi sarcoma-associated herpesvirus K1 protein: implications for lymphomagenesis. Blood
105: 3987-3994
[Abstract]
[Full Text]
-
Uddin, S., Hussain, A. R., Al-Hussein, K. A., Manogaran, P. S., Wickrema, A., Gutierrez, M. I., Bhatia, K. G.
(2005). Inhibition of Phosphatidylinositol 3'-Kinase/AKT Signaling Promotes Apoptosis of Primary Effusion Lymphoma Cells. Clin. Cancer Res.
11: 3102-3108
[Abstract]
[Full Text]
-
Jensen, K. K., Manfra, D. J., Grisotto, M. G., Martin, A. P., Vassileva, G., Kelley, K., Schwartz, T. W., Lira, S. A.
(2005). The Human Herpes Virus 8-Encoded Chemokine Receptor Is Required for Angioproliferation in a Murine Model of Kaposi's Sarcoma. J. Immunol.
174: 3686-3694
[Abstract]
[Full Text]
-
Masood, R., Xia, G., Smith, D. L., Scalia, P., Still, J. G., Tulpule, A., Gill, P. S.
(2005). Ephrin B2 expression in Kaposi sarcoma is induced by human herpesvirus type 8: phenotype switch from venous to arterial endothelium. Blood
105: 1310-1318
[Abstract]
[Full Text]
-
Paulsen, S. J., Rosenkilde, M. M., Eugen-Olsen, J., Kledal, T. N.
(2005). Epstein-Barr Virus-Encoded BILF1 Is a Constitutively Active G Protein-Coupled Receptor. J. Virol.
79: 536-546
[Abstract]
[Full Text]
-
Montaner, S., Sodhi, A., Servitja, J.-M., Ramsdell, A. K., Barac, A., Sawai, E. T., Gutkind, J. S.
(2004). The small GTPase Rac1 links the Kaposi sarcoma-associated herpesvirus vGPCR to cytokine secretion and paracrine neoplasia. Blood
104: 2903-2911
[Abstract]
[Full Text]
-
Ku, C.-C., Zerboni, L., Ito, H., Graham, B. S., Wallace, M., Arvin, A. M.
(2004). Varicella-Zoster Virus Transfer to Skin by T Cells and Modulation of Viral Replication by Epidermal Cell Interferon-{alpha}. JEM
200: 917-925
[Abstract]
[Full Text]
-
Guo, H.-G., Pati, S., Sadowska, M., Charurat, M., Reitz, M.
(2004). Tumorigenesis by Human Herpesvirus 8 vGPCR Is Accelerated by Human Immuodeficiency Virus Type 1 Tat. J. Virol.
78: 9336-9342
[Abstract]
[Full Text]
-
Nakamichi, K., Inoue, S., Takasaki, T., Morimoto, K., Kurane, I.
(2004). Rabies Virus Stimulates Nitric Oxide Production and CXC Chemokine Ligand 10 Expression in Macrophages through Activation of Extracellular Signal-Regulated Kinases 1 and 2. J. Virol.
78: 9376-9388
[Abstract]
[Full Text]
-
Krug, L. T., Pozharskaya, V. P., Yu, Y., Inoue, N., Offermann, M. K.
(2004). Inhibition of Infection and Replication of Human Herpesvirus 8 in Microvascular Endothelial Cells by Alpha Interferon and Phosphonoformic Acid. J. Virol.
78: 8359-8371
[Abstract]
[Full Text]
-
Rosenkilde, M. M., McLean, K. A., Holst, P. J., Schwartz, T. W.
(2004). The CXC Chemokine Receptor Encoded by Herpesvirus saimiri, ECRF3, Shows Ligand-regulated Signaling through Gi, Gq, and G12/13 Proteins but Constitutive Signaling Only through Gi and G12/13 Proteins. J. Biol. Chem.
279: 32524-32533
[Abstract]
[Full Text]
-
Foster-Cuevas, M., Wright, G. J., Puklavec, M. J., Brown, M. H., Barclay, A. N.
(2004). Human Herpesvirus 8 K14 Protein Mimics CD200 in Down-Regulating Macrophage Activation through CD200 Receptor. J. Virol.
78: 7667-7676
[Abstract]
[Full Text]
-
Liang, Y., Ganem, D.
(2004). RBP-J (CSL) Is Essential for Activation of the K14/vGPCR Promoter of Kaposi's Sarcoma-Associated Herpesvirus by the Lytic Switch Protein RTA. J. Virol.
78: 6818-6826
[Abstract]
[Full Text]
-
Booth, J. L., Coggeshall, K. M., Gordon, B. E., Metcalf, J. P.
(2004). Adenovirus Type 7 Induces Interleukin-8 in a Lung Slice Model and Requires Activation of Erk. J. Virol.
78: 4156-4164
[Abstract]
[Full Text]
-
Guasparri, I., Keller, S. A., Cesarman, E.
(2004). KSHV vFLIP Is Essential for the Survival of Infected Lymphoma Cells. JEM
199: 993-1003
[Abstract]
[Full Text]
-
Verzijl, D., Fitzsimons, C. P., van Dijk, M., Stewart, J. P., Timmerman, H., Smit, M. J., Leurs, R.
(2004). Differential Activation of Murine Herpesvirus 68- and Kaposi's Sarcoma-Associated Herpesvirus-Encoded ORF74 G Protein-Coupled Receptors by Human and Murine Chemokines. J. Virol.
78: 3343-3351
[Abstract]
[Full Text]
-
Liu, C., Sandford, G., Fei, G., Nicholas, J.
(2004). G{alpha} Protein Selectivity Determinant Specified by a Viral Chemokine Receptor-Conserved Region in the C Tail of the Human Herpesvirus 8 G Protein-Coupled Receptor. J. Virol.
78: 2460-2471
[Abstract]
[Full Text]
-
Tomlinson, C. C., Damania, B.
(2004). The K1 Protein of Kaposi's Sarcoma-Associated Herpesvirus Activates the Akt Signaling Pathway. J. Virol.
78: 1918-1927
[Abstract]
[Full Text]
-
Dadke, D., Fryer, B. H., Golemis, E. A., Field, J.
(2003). Activation of p21-Activated Kinase 1-Nuclear Factor {kappa}B Signaling by Kaposi's Sarcoma-Associated Herpes Virus G Protein-Coupled Receptor during Cellular Transformation. Cancer Res.
63: 8837-8847
[Abstract]
[Full Text]
-
Melchjorsen, J., Sorensen, L. N., Paludan, S. R.
(2003). Expression and function of chemokines during viral infections: from molecular mechanisms to in vivo function. J. Leukoc. Biol.
74: 331-343
[Abstract]
[Full Text]
-
Dourmishev, L. A., Dourmishev, A. L., Palmeri, D., Schwartz, R. A., Lukac, D. M.
(2003). Molecular Genetics of Kaposi's Sarcoma-Associated Herpesvirus (Human Herpesvirus 8) Epidemiology and Pathogenesis. Microbiol. Mol. Biol. Rev.
67: 175-212
[Abstract]
[Full Text]
-
Pati, S., Foulke, J. S. Jr., Barabitskaya, O., Kim, J., Nair, B. C., Hone, D., Smart, J., Feldman, R. A., Reitz, M.
(2003). Human Herpesvirus 8-Encoded vGPCR Activates Nuclear Factor of Activated T Cells and Collaborates with Human Immunodeficiency Virus Type 1 Tat. J. Virol.
77: 5759-5773
[Abstract]
[Full Text]
-
Wang, F.-Z., Akula, S. M., Sharma-Walia, N., Zeng, L., Chandran, B.
(2003). Human Herpesvirus 8 Envelope Glycoprotein B Mediates Cell Adhesion via Its RGD Sequence. J. Virol.
77: 3131-3147
[Abstract]
[Full Text]
-
Guo, H.-G., Sadowska, M., Reid, W., Tschachler, E., Hayward, G., Reitz, M.
(2003). Kaposi's Sarcoma-Like Tumors in a Human Herpesvirus 8 ORF74 Transgenic Mouse. J. Virol.
77: 2631-2639
[Abstract]
[Full Text]
-
Estep, R. D., Axthelm, M. K., Wong, S. W.
(2003). A G Protein-Coupled Receptor Encoded by Rhesus Rhadinovirus Is Similar to ORF74 of Kaposi's Sarcoma-Associated Herpesvirus. J. Virol.
77: 1738-1746
[Abstract]
[Full Text]
-
Cannon, M., Philpott, N. J., Cesarman, E.
(2002). The Kaposi's Sarcoma-Associated Herpesvirus G Protein-Coupled Receptor Has Broad Signaling Effects in Primary Effusion Lymphoma Cells. J. Virol.
77: 57-67
[Abstract]
[Full Text]
-
Polson, A. G., Wang, D., DeRisi, J., Ganem, D.
(2002). Modulation of Host Gene Expression by the Constitutively Active G Protein-coupled Receptor of Kaposi's Sarcoma-associated Herpesvirus. Cancer Res.
62: 4525-4530
[Abstract]
[Full Text]
-
Prakash, O., Tang, Z.-Y., Peng, X., Coleman, R., Gill, J., Farr, G., Samaniego, F.
(2002). Tumorigenesis and Aberrant Signaling in Transgenic Mice Expressing the Human Herpesvirus-8 K1 Gene. JNCI J Natl Cancer Inst
94: 926-935
[Abstract]
[Full Text]
-
Pati, S., Pelser, C. B., Dufraine, J., Bryant, J. L., Reitz, M. S. Jr, Weichold, F. F.
(2002). Antitumorigenic effects of HIV protease inhibitor ritonavir: inhibition of Kaposi sarcoma. Blood
99: 3771-3779
[Abstract]
[Full Text]
-
Smit, M. J., Verzijl, D., Casarosa, P., Navis, M., Timmerman, H., Leurs, R.
(2002). Kaposi's Sarcoma-Associated Herpesvirus-Encoded G Protein-Coupled Receptor ORF74 Constitutively Activates p44/p42 MAPK and Akt via Gi and Phospholipase C-Dependent Signaling Pathways. J. Virol.
76: 1744-1752
[Abstract]
[Full Text]
-
Shepard, L. W., Yang, M., Xie, P., Browning, D. D., Voyno-Yasenetskaya, T., Kozasa, T., Ye, R. D.
(2001). Constitutive Activation of NF-kappa B and Secretion of Interleukin-8 Induced by the G Protein-coupled Receptor of Kaposi's Sarcoma-associated Herpesvirus Involve Galpha 13 and RhoA. J. Biol. Chem.
276: 45979-45987
[Abstract]
[Full Text]